GO
Loading...

India

More

  • Sept 17- Auxilium Pharmaceuticals Inc adopted a poison pill with a 15 percent trigger, a day after an unsolicited $2.2 billion buyout offer from Endo International Plc.

  • General Mills profit falls 25 pct as sales decline Wednesday, 17 Sep 2014 | 7:09 AM ET

    Sept 17- General Mills Inc, the maker of Cheerios cereal and Betty Crocker cake mixes, reported a 25 percent fall in quarterly profit as sales fell for the fourth straight quarter and merchandising costs rose. The company's net income fell to $345.2 million, or 55 cents per share in the quarter ended Aug. 24, from $459.3 million, or 70 cents per share, a year earlier.

  • Sept 17- Lennar Corp, the second largest U.S. homebuilder, reported a higher-than-expected quarterly profit as it sold more homes at higher prices, and its shares rose about 6 percent in premarket trading.

  • UPDATE 1-Gilead's experimental drug fails mid-stage study Wednesday, 17 Sep 2014 | 6:47 AM ET

    Sept 17- Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening. Separately, the biotechnology company also licensed Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the drug in 91 developing nations.

  • Sept 17- Activist investor Nelson Peltz's Trian Fund Management LP, which holds a $1.6 billion stake in DuPont, called on the chemical conglomerate to separate its high-growth agriculture and other businesses from units that generate strong cash flows.

  • VWR Corp expects IPO to be priced at $22-$25/shr Wednesday, 17 Sep 2014 | 6:27 AM ET

    Sept 17- VWR Corp, a provider of laboratory supplies and services, said it expects its initial public offering of common stock to be priced between $22 and $25 per share. At the top end of the range, the company would be valued at about $3.19 billion. The company, which is offering 25.53 million shares, will raise up to $638.3 million from the float.

  • GILEAD'S EXPERIMENTAL CANCER DRUG FAILS IN MID-STAGE STUDY@. Sept 17- Gilead Sciences Inc said its experimental drug did not significantly improve the length of time that patients with a type of pancreatic cancer lived without the disease worsening.

  • UPDATE 1-Credit Suisse loans under U.S. Fed scrutiny -WSJ Wednesday, 17 Sep 2014 | 4:16 AM ET

    Federal Reserve has asked Credit Suisse to address problems relating to the bank's underwriting and sale of leveraged loans, the Wall Street Journal reported, citing a source familiar with the matter.

  • AHMEDABAD, India, Sept 17- A combination the "world's factory" and the "world's back office" will drive global economic growth, Chinese President Xi Jinping said ahead of a rare visit to India on Wednesday, playing down mistrust that has kept the Asian giants apart.

  • Trade, investment hopes as China's Xi visits India Wednesday, 17 Sep 2014 | 2:26 AM ET

    AHMEDABAD, India— Chinese President Xi Jinping landed in the Indian prime minister's home state of Gujarat on Wednesday for a three-day visit expected to focus on India's need to improve worn out infrastructure and reduce its trade deficit.

  • Sept 17- Bigger is better and Apple Inc has finally realized that and given iPhone users a product that may be low on novelty but high on improvements, reviewers wrote.

  • Activist investor Peltz wants DuPont to break up - WSJ Wednesday, 17 Sep 2014 | 1:37 AM ET

    Sept 17- Activist investor Nelson Peltz's Trian Fund Management has called for a break up of DuPont, arguing that the diversified chemicals company's overly complex and bloated corporate structure overburdens its seven business lines, the Wall Street Journal reported.

  • Credit Suisse loans under US Fed scrutiny - WSJ Wednesday, 17 Sep 2014 | 1:05 AM ET

    Federal Reserve has asked Credit Suisse Group AG to immediately address problems relating to the bank's underwriting and sale of leveraged loans, or high-interest-rate loans used by private-equity firms to finance deals, the Wall Street Journal reported, citing a source familiar with the matter.

  • *China, Singapore sentiment slips to neutral from positive. MUMBAI, Sept 17- Business sentiment among Asia's top companies fell sharply in the third quarter, weighed down by worries about China's slowing economy, a possible end to the U.S.

  • Sept 16- Endo International Plc made an unsolicited offer to buy Auxilium Pharmaceuticals Inc for about $2.2 billion, which analysts said could complicate Auxilium's buyout of Canadian eye drug maker QLT Inc.

  • Sept 16- United States Steel Corp said its Canadian arm would apply for relief from creditors under Canada's Companies' Creditors Arrangement Act and said it would drop plans to expand two of its facilities. Steel Canada, formerly known as Stelco, accounts for about $1 billion of U.S.

  • Sept 16- For-profit education companies Education Management Corp and Corinthian Colleges Inc said they would not be able to file their annual reports on time.

  • Sept 16- Specialty healthcare company Endo International Plc offered to buy Auxilium Pharmaceuticals Inc for about $2.2 billion in cash and stock to expand its men's healthcare products business.

  • UPDATE 2-Adobe revenue forecast misses, shares slip Tuesday, 16 Sep 2014 | 6:22 PM ET

    Sept 16- Photoshop maker Adobe Systems Inc's forecast disappointing revenue for this quarter and reported lower quarterly sales at its digital media business, which includes the Creative Cloud software suite. The company said it expected adjusted profit of 26- 32 cents per share on revenue of $1.03 billion- $1.08 billion for the quarter ending November.

  • FedEx units to raise shipping rates from January Tuesday, 16 Sep 2014 | 5:34 PM ET

    Sept 16- FedEx Corp, the world's No.2 package delivery company, said it would increase shipping rates for its express, ground and freight services, effective Jan. 5, 2015. The rate change applies to FedEx freight shipments within the United States, Canada and Mexico as well as between the U.S. and Canada and between the U.S. and Mexico, FedEx said.